Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO, BIOB · Entity 2247 | EVP and CFO | December 14, 2018 | December 17, 2018 |
| Envista Holdings CorpNVST · Entity 4007 | Director | May 19, 2026 | May 21, 2026 |
| Telesis Bio Inc.TBIO · Entity 15606 | Director | July 06, 2023 | May 03, 2024 |
| Varex Imaging CorpVREX · Entity 5135 | Director | February 12, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date December 14, 2018 · Filed December 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 6,683.0979 |
Reported balance
After 2018-12-14 transaction · row 1
1 source rowRow 1 · 2018-12-14 · Sale · Disposed 1,411 · Balance 6,683.0979 |
Envista Holdings Corp
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,930 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 9,330 · Balance 59,930 F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis.
Telesis Bio Inc.
Report date July 06, 2023 · Filed May 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,491 |
Ending reported balance
After 2024-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-06 · Grant · Acquired 46,752 · Balance 67,382 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through such date, 100% of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. Row 2 · 2024-05-01 · Grant · Acquired 37,109 · Balance 104,491 F2: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through each applicable date, 16,868 of the RSUs shall vest on January 1, 2025, and 20,241 of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2033-07-06 | Direct | 70,129 |
Reported balance
After 2023-07-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-06 · Grant · Acquired 70,129 · Balance 70,129 F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2034-05-01 | Direct | 30,362 |
Reported balance
After 2024-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-01 · Grant · Acquired 30,362 · Balance 30,362 F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through such date, 100% of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
F2: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through each applicable date, 16,868 of the RSUs shall vest on January 1, 2025, and 20,241 of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
Varex Imaging Corp
Report date February 12, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,331 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 12,331 · Balance 12,331 F1: Each Deferred Stock Unit converts into common stock on a one-for-one basis. F2: These Deferred Stock Units vest 100% on the earlier of (i) the one-year anniversary of the date of the grant and (ii) the next annual meeting of stockholders that occurs after the date of grant. Vested shares will be delivered to the reporting person upon the earlier of (i) the third anniversary of the date of grant (ii) a change in control or (iii) the reporting person's termination of service for any reason. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Stock Unit converts into common stock on a one-for-one basis.
F2: These Deferred Stock Units vest 100% on the earlier of (i) the one-year anniversary of the date of the grant and (ii) the next annual meeting of stockholders that occurs after the date of grant. Vested shares will be delivered to the reporting person upon the earlier of (i) the third anniversary of the date of grant (ii) a change in control or (iii) the reporting person's termination of service for any reason.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ONTO INNOVATION INC.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2016 Filed Sep 9, 2016 18:59 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000083 · edgar.xml · derivative · entry 3 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires 2026-09-07 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:59 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000083 · edgar.xml · derivative · entry 2 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.